Physician profile
Cima Nowbakht
NPI 1699113910
$4,127.75
in general payments reported to CMS, 2019-2025
18 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $149 · 2021: $167 · 2022: $525 · 2023: $1,487 · 2024: $509 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666 · Consulting Fee: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.03 |
| Consulting Fee | $1,380.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $1,402.13 | 2023-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $661.01 | 2019-2025 | Zerbaxa, Prevymis, Dificid |
| Gilead Sciences, INC. | $467.31 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $316.09 | 2019-2025 | Nuzyra |
| Viiv Healthcare Company | $269.99 | 2021-2025 | Cabenuva, Dovato |
| Abbvie INC. | $225.53 | 2024-2025 | |
| Melinta Therapeutics, LLC | $114.95 | 2024-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Insmed, INC. | $112.85 | 2020-2025 | Arikayce, Brinsupri |
| Angiodynamics, INC. | $109.13 | 2024 | Angiovac |
| Shionogi INC | $97.25 | 2022-2025 | Fetroja |
| Cumberland Pharmaceuticals, INC. | $93.12 | 2025 | Vibativ |
| Mayne Pharma Commercial LLC | $92.80 | 2019 | |
| La Jolla Pharmaceutical Company | $50.68 | 2023-2024 | Xerava |
| Invivyd INC | $41.55 | 2024-2025 | Pemgarda |
| Octapharma USA, INC. | $27.40 | 2024 | Panzyga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $27.22 | 2020-2021 | |
| Allergan, INC. | $18.74 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cima Nowbakht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.